Skip to content

Study · Animal study (in vivo) · 2006

3 results

Effects of semax against the background of dopaminergic receptor blockade with haloperidol.

Sebentsova EA, Levitskaya NG, Andreeva LA, Alfeeva LY, Kamenskii AA, Myasoedov NF

Bulletin of experimental biology and medicine1 Feb 2006

PMID16984088 (opens in a new tab)DOI10.1007/s10517-006-0119-y (opens in a new tab)PepBankPUB-16984088
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    Intranasal Semax produced virtually no effect on haloperidol-induced disturbances of orientation and exploratory reactions.

    In plain wordsIn animals given haloperidol, Semax given through the nose had almost no effect on orientation and exploring behaviour.

    Peptide
    Semax
    Outcome
    No significant changeHaloperidol-induced disturbance of orientation and exploratory reactions
    Study

    n: not reported in source

    Haloperidol-induced dopamine receptor blockade
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    0.05, 0.2, and 0.6 mg/kg · intranasalAs given in this study.

    Source sentences

    Summary
    Intranasal administration of semax (0.05, 0.2, and 0.6 mg/kg) produced virtually no effect on disturbances of orientation and exploratory reactions and motor activity caused by intraperitoneal injection of 0.2 mg/kg haloperidol.
    1 context sentence
    Summary · context
    We studied the neurotropic effects of ACTH(4-10) analog semax against the background of dopaminergic receptors blockade with haloperidol.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    Intranasal Semax produced virtually no effect on haloperidol-induced disturbances of motor activity.

    In plain wordsIn animals given haloperidol, Semax given through the nose had almost no effect on movement.

    Peptide
    Semax
    Outcome
    No significant changeHaloperidol-induced disturbance of motor activity
    Study

    n: not reported in source

    Haloperidol-induced dopamine receptor blockade
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    0.05, 0.2, and 0.6 mg/kg · intranasalAs given in this study.

    Source sentences

    Summary
    Intranasal administration of semax (0.05, 0.2, and 0.6 mg/kg) produced virtually no effect on disturbances of orientation and exploratory reactions and motor activity caused by intraperitoneal injection of 0.2 mg/kg haloperidol.
    1 context sentence
    Summary · context
    We studied the neurotropic effects of ACTH(4-10) analog semax against the background of dopaminergic receptors blockade with haloperidol.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    Preliminary administration of Semax prevented haloperidol-induced disturbances in active avoidance conditioning.

    In plain wordsIn animals given haloperidol, a low dose of Semax given beforehand prevented problems with learning an avoidance task.

    Peptide
    Semax
    Outcome
    DecreaseHaloperidol-induced disturbance of active avoidance conditioning
    Study

    n: not reported in source

    Haloperidol-induced dopamine receptor blockade
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    0.05 mg/kgAs given in this study.

    Source sentences

    Summary
    By contrast, preliminary administration of 0.05 mg/kg semax prevented haloperidol-induced disturbances in active avoidance conditioning.
    1 context sentence
    Summary · context
    We studied the neurotropic effects of ACTH(4-10) analog semax against the background of dopaminergic receptors blockade with haloperidol.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.